Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention deficit hyperactivity disorder

Judith M. Lionarons*, Danique M. J. Hellebrekers, Sylvia Klinkenberg, Catharina G. Faber, Johan S. H. Vies, Jos G. M. Hendriksen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)
40 Downloads (Pure)

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a common comorbidity in Duchenne muscular dystrophy (DMD). Until now, treatment with methylphenidate (MPH) has never been systematically assessed and described in this population. Our aim was to evaluate the effectiveness and safety of short acting MPH for learning problems in males with DMD and ADHD. Neuropsychological (cognition and behavior) and medical data of a sample of ten males (mean age = 8.1 years, range 6.3-9.8) with DMD and an ADHD diagnosis was retrospectively analyzed at baseline (TO; without MPH), short-term follow-up (T1; with MPH; mean interval T0-T1 = 8.3 months, range 4.3-15.6), and long-term follow-up (T2; mean interval T1-T2 = 23.1 months, range 2.6-77.7). An initial MPH dose of 5 mg/day was given on school mornings, with an increase of 2.5-5 mg/week depending on individual tolerance and treatment response, until a sufficiently effective dose was reached (range 0.2-0.6 mg/kg/day). At T1, results demonstrated an improvement in attention (i.e. concentration, impulsivity, and distractibility) in four patients. Suboptimal effects were reported in four patients, and no effects in two patients. At T2, seven patients showed considerable improvement in attention. No major side effects were reported. Overall, our data show that short acting MPH can be clinically effective for learning problems in males with DMD and ADHD, with regular cardiac follow-up, and close monitoring of side effects and neuropsychological effects. Furthermore, this underscores the importance of the use of validated cognitive and behavioral measurement tools with adequate sensitivity to objectively evaluate the effect of MPH. (C) 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)152-157
Number of pages6
JournalEuropean Journal of Paediatric Neurology
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • Duchenne muscular dystrophy
  • Attention-deficit hyperactivity disorder
  • Neuropsychological evaluation
  • Methylphenidate
  • ADHD
  • CHILDREN
  • ADOLESCENTS
  • MANAGEMENT
  • DIAGNOSIS
  • MELATONIN
  • STIMULANT
  • SAFETY
  • SLEEP
  • BRAIN

Cite this